Cardiac toxicity in breast cancer patients treated with dual HER2 blockade (Q34694972)

4 August 2017

0 references

Cardiac toxicity in breast cancer patients treated with dual HER2 blockade (English)

1 reference

4 August 2017

Antonis Valachis

1

1 reference

4 August 2017

Andreas Nearchou

series ordinal

2

1 reference

4 August 2017

Nikolaos P Polyzos

series ordinal

3

1 reference

4 August 2017

Pehr Lind

series ordinal

4

1 reference

4 August 2017

language of work or name

English

0 references

publication date

29 May 2013

1 reference

International Journal of Cancer

4 August 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

4 August 2017

volume

133

1 reference

4 August 2017

issue

9

1 reference

4 August 2017

page(s)

2245-2252

1 reference

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

4 August 2017

cites work

1 reference

Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review

21 January 2018

1 reference

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

Cardiac dysfunction in the trastuzumab clinical trials experience

21 January 2018

1 reference

Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations

21 January 2018

1 reference

Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes

21 January 2018

1 reference

The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy

21 January 2018

1 reference

Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study

21 January 2018

1 reference

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study

21 January 2018

1 reference

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

21 January 2018

1 reference

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

21 January 2018

1 reference

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

21 January 2018

1 reference

Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab

21 January 2018

1 reference

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

21 January 2018

1 reference

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

21 January 2018

1 reference

What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data

21 January 2018

1 reference

Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.

21 January 2018

1 reference

Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?

21 January 2018

1 reference

Meta-analysis of rare and adverse event data

21 January 2018

1 reference

Jumping higher: is it still possible? The ALTTO trial challenge

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.28234

1 reference

4 August 2017

1 reference